Clinical Trials in South Korea / NCT05103683
Recruiting
Phase 1
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683 · tracked via the Priya Life Science South Korea tracker
Condition(s) studied
Advanced Solid TumorOvarian CancerEndometrial CancerNSCLC
Study summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Eligibility
Inclusion Criteria:
* Advanced solid tumor
* Measurable disease, per RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Adequate organ function
Exclusion Criteria:
* Has not recovered \[recovery is defined as NCI CTCAE, version 5.0, grade ≤1\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements
* Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23
* Progressive or symptomatic brain metastases
* Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
* History of significant cardiac disease
* History of myelodysplastic syndrome (MDS) or AML
* History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded
* If female, is pregnant or breastfeeding
Primary outcome measure(s)
- Incidence and severity of adverse events and serious adverse events — up to 2 years
Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0 - Maximum Tolerated Dose (MTD) — 28 Days
Highest administered dose with \< 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants - Recommended Phase 2 Dose (RP2D) — up to 2 years
Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data
Trial sites (14)
| Facility | City | Region | Status |
|---|---|---|---|
| Providence Medical Foundation | Fullerton | California | Recruiting |
| UCLA - JCCC Clinical Research Unit | Los Angeles | California | Recruiting |
| University of Kentucky Medical Center | Lexington | Kentucky | Recruiting |
| University of Minnesota | Minneapolis | Minnesota | Recruiting |
| Mayo Clinic in Rochester | Rochester | Minnesota | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | Recruiting |
| Sarah Cannon Research Institute Texas Oncology | Tyler | Texas | Recruiting |
| Virginia Cancer Specialists | Fairfax | Virginia | Recruiting |
| St. Vincent's Hospital, The Catholic University of Korea | Suwon | Gyeonggi-do | Recruiting |
| Seoul National University Hospital | Seoul | South Korea | Recruiting |
| Severance Hospital | Seoul | South Korea | Recruiting |
| Asan Medical Center | Seoul | South Korea | Recruiting |
| Samsung Medical Center | Seoul | South Korea | Recruiting |
More TORL Biotherapeutics, LLC trials in South Korea
Other trials for the same condition
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Recruiting
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Active, not recruiting
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Active, not recruiting
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05103683 on ClinicalTrials.gov ↗ ← All trials in South Korea